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Abstract
Background: Growth hormone (GH) treatment has become a frequently applied growth promoting therapy in short
children born small for gestational age (SGA). Children born SGA have a higher risk of developing attention deficit
hyperactivity disorder (ADHD). Treatment of ADHD with methylphenidate (MP) has greatly increased in recent years,
therefore more children are being treated with GH and MP simultaneously. Some studies have found an association
between MP treatment and growth deceleration, but data are contradictory.
Objective: To explore the effects of MP treatment on growth in GH-treated short SGA children
Methods: Anthropometric measurements were performed in 78 GH-treated short SGA children (mean age 10.6 yr), 39 of
whom were also treated with MP (SGA-GH/MP). The SGA-GH/MP group was compared to 39 SGA-GH treated subjects. They
were matched for sex, age and height at start of GH, height SDS at start of MP treatment and target height SDS. Serum
insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) levels were yearly determined. Growth, serum IGF-I
and IGFBP-3 levels during the first three years of treatment were analyzed using repeated measures regression analysis.
Results: The SGA-GH/MP group had a lower height gain during the first 3 years than the SGA-GH subjects, only significant
between 6 and 12 months of MP treatment. After 3 years of MP treatment, the height gain was 0.2 SDS (60.1 SD) lower in
the SGA-GH/MP group (P = 0.17). Adult height was not significantly different between the SGA-GH/MP and SGA-GH group
(21.9 SDS and 21.9 SDS respectively, P = 0.46). Moreover, during the first 3 years of MP treatment IGF-I and IGFBP-3
measurements were similar in both groups.
Conclusion: MP has some negative effect on growth during the first years in short SGA children treated with GH, but adult
height is not affected.
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Introduction
Short stature persists in approximately 10% of children born
small for gestational age (SGA) [1]. Growth hormone (GH)
treatment has become a frequently applied growth promoting
therapy and results in significant catch-up growth [2]. Children
born SGA have a higher risk of developing attention deficit
hyperactivity disorder (ADHD) [3,4]. ADHD is one of the most
commonly encountered behavioral problems in childhood. Treat-
ment of ADHD with stimulant drugs, such as methylphenidate
(MP), has greatly increased in recent years [5,6]. MP has been
associated with growth deceleration, specifically during the first
years of treatment [7,8,9,10,11,12,13,14].
An increasing number of children are being treated with both
GH and a stimulant drug [15]. Data regarding the effect of
stimulant medication on growth in children treated with GH are
limited. Children with idiopathic GH deficiency treated with GH
are reported to have a significant smaller height gain if a stimulant
drug is being used simultaneously [15,16]. This suggests that
simultaneous use of stimulant medication and GH might not be
advised.
The cause of the decelerated growth during MP use has not yet
been elucidated. One proposed mechanism is loss of appetite
which leads to less weight gain [12]. Another possible cause may
be the altered dopaminergic pathways in ADHD. These pathways
are also involved in GH secretion and MP treatment decreases the
re-uptake of dopamine and noradrenalin [17,18,19]. Both
proposed mechanisms can lead to less GH secretion and lower
serum levels of insulin-like growth factor I (IGF-I) and IGF-
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binding protein-3 (IGFBP-3), which both play a central role in
postnatal growth.
We hypothesized that simultaneous use of GH and MP would
negatively affect the growth response to GH therapy, because of
lower serum IGF-I and IGFBP-3 levels. To determine the effect of
MP on growth we ideally should have randomly assigned MP
treatment to two groups of patients. However, since the
effectiveness of MP has been established in various studies this
was ethically not feasible [20]. In this paper we retrospectively
report height and weight gain, and adult height in short SGA
children treated with GH and MP and compare these data with
matched GH-treated SGA subjects without MP. We also describe
the effect of MP on serum IGF-I and IGFBP-3 levels.
Patients and Methods
Subjects
The study cohort consisted of 427 short children born SGA who
participated in four GH trials. The inclusion criteria for these
studies have previously been described [21,22,23,24,25]. In short,
children were included according to the following criteria: 1) birth
length and/or birth weight standard deviation score (SDS) below
22.0 for gestational age [26], 2) height SDS for calendar age (CA)
below 22.0 according to Dutch standards at start of GH
treatment [27], 3) height velocity SDS below zero to exclude
children with spontaneous catch-up growth.
For the present study we included 78 subjects, 39 of them
received MP for $6 months (SGA-GH/MP) and 39 GH treated
children born SGA (SGA-GH) who had never been exposed to
MP treatment. Each subject in the SGA-GH/MP treated group
was individually matched to an SGA-GH subject based on sex, age
and height at start of GH treatment, height SDS at start of MP
treatment and target height (TH) SDS. The delta accepted for
each parameter was 0.5 SDS. Of the 39 SGA-GH/MP subjects,
13 had been on MP treatment before the start of GH treatment.
Study protocols were approved by the Medical Ethics Committee
of all participating centers (Erasmus Medical Center, Admiraal de
Ruyter Hospital, Canisius Hospital, Catharina Hospital, Free
University Medical Center, Isala Clinics, Juliana Children’s
Hospital, Leiden University Medical Center, University Medical
Center Groningen, University Medical Center Radboud, Rijnstate
Hospital, Walcheren Hospital, Wilhelmina Children’s Hospital,
and Zaans Medisch Centrum) and written informed consent was
obtained from all participants and/or their parents.
Study design
During GH treatment, height, weight and Tanner stage were
determined every 3 months as previously described [22]. Children
were treated with biosynthetic growth hormone approximately
1 mg/m2/day which was administered once daily at bedtime.
Body mass index (BMI) was calculated as weight divided by height
squared (kg/m2). Target height (TH) was calculated as TH= [(ma-
ternal height+paternal height+13)/2+4.5] for boys and
TH= [(maternal height+paternal height213)/2+4.5] for girls.
Height, BMI and TH were expressed in SDS, adjusting for sex
and age according to Dutch reference data for children [27]. The
onset of puberty was defined as breast development stage 2
according to Tanner for girls and testicular volume$4 ml for boys
[28].
Biochemical measurements. Blood samples were taken at
baseline and yearly during GH treatment. After centrifugation, all
samples were frozen (280uC) until assayed. RIA measurements of
serum IGF-I and serum IGFBP-3 levels were performed in one
laboratory as previously described [29]. Levels of IGF-I and
IGFBP-3 were expressed as SDS, adjusting for age and gender,
using reference values from healthy children of normal stature
[30].
Statistical analysis. A paired-sample t-test was used to
compare the SGA-GH/MP group with the matched controls in
the SGA-GH group. The Wilcoxon signed-ranks test was used to
compare age at start of puberty. Height gain SDS was analyzed
from start of MP treatment over 3 years. If MP treatment had
started before GH treatment we analyzed data from start of GH
treatment. The longest consecutive period of MP treatment was
used when analyzing the data. The changes over time were
analyzed with repeated measures regression analysis to correct for
multiple testing and missing data ($1 yr use of MP in 36 subjects,
$2 yrs n= 26 and $3 yrs n = 20). The effect of MP treatment was
estimated separately for three time periods, the first 6 months, for
6 to 12 months and for the period after 12 months. Also, the effect
for the period after stop of MP treatment was estimated. The
analysis of height gain SDS was adjusted for sex, TH SDS, age at
start of GH treatment, puberty, GH dose, gonadotropin releasing
hormone analogue use (n = 8) and duration of GH treatment
before start of MP treatment. The analysis of gain in BMI SDS
was adjusted for the same variables except for TH SDS. Adult
height (AH) was defined as the condition when height velocity
dropped ,0.5 cm during the previous 6 months. AH SDS was
calculated based on Dutch reference data for age 21 years [27].
Corrected AH was calculated by subtracting the TH SDS from the
AH SDS. Difference in AH SDS and corrected AH SDS within
the matched pairs was analyzed with a repeated measures model
correcting for age and height SDS at start of GH treatment, TH
SDS, age at start of puberty and GH dose. IGF-I and IGFBP-3
SDS data were adjusted for duration of GH treatment before start
of MP treatment, GH dose and puberty. A P-value,0.05 was
considered significant. Analyses were performed using the
statistical package SPSS for Windows (version 17.0; SPSS Inc.,
Chicago, IL). For repeated measures regression analysis SAS 8.2
(SAS Institute Inc., Cary, /nC, USA) was used.
Results
Baseline characteristics
Of the total study group, 39 subjects were treated with MP
(,10%). Clinical characteristics of the SGA-GH/MP and SGA-
GH subjects are shown in Table 1. MP treatment was more
common in boys than in girls (31 boys and 8 girls). There were no
significant differences between the SGA-GH/MP and SGA-GH
group. Mean (6SD) age at start of MP treatment was 10.6 (62.2)
yr and mean duration of MP treatment was 3.7 (62.5) yr. The
mean dose of MP was 28.2 (613.4) mg/day.
Growth
Figure 1 shows the height gain SDS in the two groups. Height
gain was not significantly different between the two groups during
the first 6 months of MP treatment (0.005 SDS, P= 0.85), but
between 6 and 12 months, the SGA-GH/MP group had a
significantly smaller height gain SDS than the SGA-GH group
(20.05 SDS, P= 0.03). Between 1 and 3 years of MP treatment,
the height gain SDS was also smaller in the SGA-GH/MP group
but not significantly, with a difference of 20.04 SDS (P= 0.06) in
every six months. After 3 years, the difference between the two
groups amounted to 0.2 SDS (P= 0.17).
Adult height was reached in 25 of the 39 SGA-GH/MP subjects
(64%) and in 28 of the 39 SGA-GH subjects (72%). Mean age at
reaching AH was 17.3 (61.2) yr for boys and 16.0 (60.9) for girls
in the SGA-GH/MP group and 16.9 (61.2) yr for boys and 15.6
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(60.5) yr for girls in the SGA-GH group (boys P= 0.26 and girls
P = 0.41). In the SGA-GH/MP group, the mean duration of MP
treatment was 4.6 (62.6) yr and of GH treatment was 8.1 (62.5)
yr. In the SGA-GH group the duration of GH treatment was 7.8
(62.3) yr. Mean AH was 21.9 (60.7) SDS in the SGA-GH/MP
and 21.9 (60.6) SDS in the SGA-GH group. AH between the
groups was not significantly different (adjusted difference 0.07
SDS, P= 0.57). Corrected AH was 21.4 (60.8) SDS in the SGA-
GH/MP and 21.4 (60.7) in the SGA-GH group, this was not
significantly different (adjusted difference 0.09 SDS, P= 0.44).
At start of MP treatment, the BMI SDS was 21.0 (61.0) SDS
in the SGA-GH/MP group and20.7 (61.1) SDS in the SGA-GH
subjects. During the first 6 months of MP treatment, the gain in
BMI SDS was not significantly different between the two groups
(20.09 SDS, P= 0.13). However, between 6 and 12 months the
SGA-GH/MP group had a significantly larger gain in BMI SDS
than the SGA-GH group (0.13 SDS, P= 0.02). Between 1 and 3
years, the six-monthly BMI gain SDS was not significantly
different between the two groups (0.02 SDS, P= 0.52).
After cessation of MP treatment, there was no acceleration of
growth after six months (height gain SDS 0.03 SDS, P= 0.36)
compared to the controls. There was also no acceleration in BMI
SDS gain, six months after discontinuation of MP (0.02 SDS,
P= 0.74).
IGF-I and IGFBP-3 levels
Serum IGF-I and IGFBP-3 SDS levels are shown in Figure 2.
The gain in IGF-I SDS was not significantly different between the
SGA-GH/MP and SGA-GH group during three years of MP
treatment (20.07 SDS, P= 0.75). The gain in serum IGFBP-3
SDS was higher in the SGA-GH/MP group, but not significantly
so (0.37 SDS, P= 0.06). The IGF-I/IGFBP-3 ratio SDS was also
not significantly different between the SGA-GH/MP and SGA-
GH group (20.09 SDS, P= 0.76).
Discussion
In this study we investigated the effect of methylphenidate (MP)
treatment on growth in short children born SGA treated with GH.
We analyzed growth during the first 3 years of MP in addition to
GH treatment and also adult height. We showed that the 3-year
height gain was 0.2 SDS smaller in children treated with MP than
in non-MP-treated children, but not significant. Reassuringly,
there was no difference in adult height between the SGA-GH/MP
group and the SGA-GH group. The gain in BMI SDS was not
negatively affected by MP treatment and IGF-I and IGFBP-3
levels were also not significantly different between the two groups.
ADHD is a disorder of hyperactivity, inattention and impulsiv-
ity that affects approximately 5% of children in the Netherlands
[6]. The most frequently prescribed drugs in the treatment of
ADHD are stimulant drugs, such as MP [5,6]. Since the use of
stimulant drugs has increased substantially in recent years more
children are being treated with GH and MP simultaneously
[5,6,15]. In our cohort of short SGA children, approximately 10%
were being treated with MP, which is considerably higher than the
reported 5%, indicating that ADHD seems to occur more
frequently in children born SGA. This is in line with data
reported by van der Reijden-Lakeman and Groen-Blokhuis et al
[4,31].
Simultaneous use of MP during GH treatment has been
associated with growth deceleration, specifically during the first
years of treatment [15,16]. We showed that after 3 years of GH
treatment, the difference between the SGA-GH/MP and SGA-
GH group was 0.2 SDS. These results are in line with Rao et al.,
who reported a negative effect on height gain of 0.17 SDS during
3 years of MP treatment [16]. It demonstrates that there is a small
Table 1. Patient characteristics.
SGA-GH/MP SGA-GH P-value
Male/female 31/8 31/8 1.00
Age at start GH 8.7 (2.9) 8.7 (2.8) 0.93
Height SDS at start GH 22.7 (0.9) 22.8 (0.5) 0.60
Target Height SDS 20.37 (0.7) 20.40 (0.7) 0.72
Weight SDS at start MP 22.1 (1.2) 21.8 (1.2) 0.08
BMI SDS at start MP 21.0 (1.0) 20.7 (1.1) 0.18
Age at start puberty (yr), male 12.5 (10.2 to 14.7) 12.4 (10.0 to 12.4) 0.70
Age at start puberty (yr), female 11.0 (9.9 to 11.8) 10.9 (9.8 to 11.9) 0.89
Values are expressed as mean (SD). Age at start puberty is expressed as median (interquartile range). BMI = body mass index; GH=growth hormone;
MP=methylphenidate; SDS = standard deviation score; SGA= small for gestational age.
doi:10.1371/journal.pone.0053164.t001
Figure 1. Height gain SDS during 3 years of MP treatment. Data
are expressed as model estimates (standard error), $1 yr use of MP in
36 subjects, $2 yrs n = 26 and $3 yrs n = 20. GH=growth hormone;
MP=methylphenidate; SGA= small for gestational age; SDS= standard
deviation score.
doi:10.1371/journal.pone.0053164.g001
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but distinct risk of diminished growth during the first years of MP
treatment in GH-treated short SGA children.
Data on adult height are very limited. To our knowledge, there
are no reports on adult height in subjects treated with both GH
and MP. Our study shows no significant difference in adult height
SDS between the SGA-GH/MP and SGA-GH group (0.07 SDS,
p= 0.46) which suggests that the initial loss of height gain has no
long-term adverse effect on adult height. Earlier reports investi-
gating adult height in children treated with only MP did not find
any effects either, despite significant effects on height and weight
during the first years of treatment [32,33,34,35]. A possible
explanation might be catch-up growth after cessation of MP
treatment. However, we found no increase in height gain SDS 6
months after discontinuation of MP (0.03 SDS, P= 0.36), despite
reports that cessation of MP treatment results in catch-up growth
[36,37,38].
The mechanism by which MP affects growth is not completely
understood. Decreased appetite leading to reduced weight gain
has been proposed as a cause of growth reduction [12]. We did not
find that MP negatively influenced gain in BMI SDS during three
years of treatment. In fact, during the second half of the first year
of MP treatment gain in BMI SDS was higher in the SGA-GH/
MP group. This might be explained by the low weight SDS at the
start of MP treatment (22.1 SDS). Parents are perhaps being
made more aware of reduced appetite as possible side effect of MP
and tend to ‘‘overfeed’’ their children to prevent a reduction in
weight. Furthermore, the negative effect of MP on weight gain
appears to be more pronounced in children who are overweight,
which is not the case in short SGA children [10,39].
Another cause of the decelerated growth may be that MP has a
negative influence on the re-uptake of dopamine, a hormone that
is involved in the regulation of GH secretion. The effects of GH
are mediated by IGF-I. Although gain in serum IGF-I levels was
lower in the SGA-GH/MP group, this difference was not
significant. Gain in serum IGFBP-3 levels was higher in the
SGA-GH/MP group, but again not significantly so. The lower
serum IGF-I and higher serum IGFBP-3 levels could result in
reduced free IGF-I levels. However, the gain in IGF-I/IGFBP-3
ratio SDS was not significantly lower in the SGA-GH/MP group.
Other studies on the effect of MP on GH, serum IGF-I and
IGFBP-3 levels are contradictory. Bereket et al showed that MP
caused a transient decrease in IGF-I and IGFBP-3 levels [19]. On
the other hand a study by Toren et al. found no difference in GH,
GH binding protein and IGF-I levels [40]. Our results suggest that
the cause of growth deceleration does not seem to be the result of
significantly lower IGF-I and IGFBP-3 levels.
In this study we measured height and weight every 3 months
enabling us to accurately assess growth patterns. In this study
thirteen subjects had been treated with MP before the start of GH.
Since the negative effects on growth are most pronounced during
the first years of MP treatment, it is possible that we have
underestimated the decrease in height gain. Furthermore,
although our study followed the growth of short SGA children
treated with both GH and MP, we did not follow a stimulant-
untreated ADHD control group. Ideally the start of stimulant
medication should be randomized. However, since the efficacy of
MP treatment has been well established such a design was
considered unethical [20].
In conclusion, physicians should be aware that height gain can
be somewhat reduced during the first years of MP treatment in
children treated with GH. It is however reassuring that adult
height does not seem to be affected. Growth deceleration during
the first years of MP treatment does not seem to be mediated
through a reduced BMI gain or a reduction in IGF-I and IGFBP-3
levels.
Acknowledgments
We thank all patients and their parents for participating in this study. We
greatly acknowledge Mrs. C. Bruinings-Vroombout, Mrs. J. Dunk, Mrs. M.
Huibregtse-Schouten, Mrs. J. van Houten, Mrs. J. van Nieuwkasteele,
research nurses, for their assistance and help with data collection.
Participating physicians were: J. Rotteveel, Free University Hospital
Amsterdam, The Netherlands; J. C. Mulder, Rijnstate Hospital, Arnhem,
The Netherlands; R. J. H. Odink, Catharina Hospital, Eindhoven, The
Netherlands; W. M. Bakker-van Waarde, University Medical Center
Groningen, Groningen, The Netherlands; W. Oostdijk, Leiden University
Medical Center, Leiden, The Netherlands; C. Noordam, Radboud
University Medical Center Nijmegen, Nijmegen, The Netherlands; C.
Westerlaken, Canisius Hospital, Nijmegen, The Netherlands; N. J. T.
Figure 2. IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratio gain SDS
values during 3 years of MP treatment. Data are expressed as
model estimates (standard error). IGF-I = insulin-like growth factor;
IGFBP-3 = insulin-like growth factor binding protein-3; MP=methylphe-
nidate; SGA= small for gestational age; SDS = standard deviation score.
doi:10.1371/journal.pone.0053164.g002
MP and the Response to GH in Short SGA Children
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e53164
Arends, V. H. Boonstra, R. H. Willemsen, M. Van Dijk, S. W. K de Kort,
D. C. M. van der Kaay, T. C. J. Sas, Erasmus Medical Center Sophia,
Rotterdam, The Netherlands; E. C. A. M. Houdijk, Juliana Children’s
Hospital, The Hague, The Netherlands; E.J. Schroor, Isala clinics, Zwolle,
The Netherlands, J.P.C.M. van der Hulst, Zaans medical centre,
Zaandam, The Netherlands; E.J. Sulkers, Walcheren Hospital, Vlissingen,
The Netherlands and M. Jansen, Wilhelmina Children’s Hospital, Utrecht,
The Netherlands.
Author Contributions
Conceived and designed the experiments: JSR AH-K. Analyzed the data:
JSR MAJR AH-K. Wrote the paper: JSR. Acquisitioned and interpreted
the data: JSR PEB AJL AH-K MAJR. Carefully revised the content of the
article and approved the final version: MAJR PEB AJL AH-K.
References
1. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck
Keizer-Schrama SM, et al. (1995) Children born small for gestational age: do
they catch up? Pediatr Res 38: 267–271.
2. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, et al. (2003) Adult
height after long-term, continuous growth hormone (GH) treatment in short
children born small for gestational age: results of a randomized, double-blind,
dose-response GH trial. J Clin Endocrinol Metab 88: 3584–3590.
3. Lahti J, Raikkonen K, Kajantie E, Heinonen K, Pesonen AK, et al. (2006) Small
body size at birth and behavioural symptoms of ADHD in children aged five to
six years. J Child Psychol Psychiatry 47: 1167–1174.
4. Groen-Blokhuis MM, Middeldorp CM, van Beijsterveldt CE, Boomsma DI
(2011) Evidence for a causal association of low birth weight and attention
problems. J Am Acad Child Adolesc Psychiatry 50: 1247–1254 e1242.
5. Zuvekas SH, Vitiello B, Norquist GS (2006) Recent trends in stimulant
medication use among U.S. children. Am J Psychiatry 163: 579–585.
6. Donker GA, Groenhof F, van der Veen WJ (2005) [Increasing trend in
prescription of methylphenidate in general practices in the north-east of The
Netherlands, 1998–2003] Toenemend aantal voorschriften voor methylfenidaat
in huisartspraktijken in Noordoost-Nederland, 1998–2003. Ned Tijdschr
Geneeskd 149: 1742–1747.
7. Group MTAC (2004) National Institute of Mental Health Multimodal
Treatment Study of ADHD follow-up: changes in effectiveness and growth
after the end of treatment. Pediatrics 113: 762–769.
8. Mattes JA, Gittelman R (1983) Growth of hyperactive children on maintenance
regimen of methylphenidate. Arch Gen Psychiatry 40: 317–321.
9. Safer D, Allen R, Barr E (1972) Depression of growth in hyperactive children on
stimulant drugs. N Engl J Med 287: 217–220.
10. Gross MD (1976) Growth of hyperkinetic children taking methylphenidate,
dextroamphetamine, or imipramine/desipramine. Pediatrics 58: 423–431.
11. Satterfield JH, Cantwell DP, Schell A, Blaschke T (1979) Growth of hyperactive
children treated with methylphenidate. Arch Gen Psychiatry 36: 212–217.
12. Spencer T, Biederman J, Wright V, Danon M (1992) Growth deficits in children
treated with desipramine: a controlled study. J Am Acad Child Adolesc
Psychiatry 31: 235–243.
13. Zhang H, Du M, Zhuang S (2010) Impact of long-term treatment of
methylphenidate on height and weight of school age children with ADHD.
Neuropediatrics 41: 55–59.
14. Poulton A, Cowell CT (2003) Slowing of growth in height and weight on
stimulants: a characteristic pattern. J Paediatr Child Health 39: 180–185.
15. Frindik JP, Morales A, Fowlkes J, Kemp S, Thrailkill K, et al. (2009) Stimulant
medication use and response to growth hormone therapy: an NCGS database
analysis. Horm Res 72: 160–166.
16. Rao JK, Julius JR, Breen TJ, Blethen SL (1998) Response to growth hormone in
attention deficit hyperactivity disorder: effects of methylphenidate and pemoline
therapy. Pediatrics 102: 497–500.
17. Barter M, Kammer H (1978) Methylphenidate and growth retardation. Jama
239: 1742–1743.
18. Aarskog D, Fevang FO, Klove H, Stoa KF, Thorsen T (1977) The effect of the
stimulant drugs, dextroamphetamine and methylphenidate, on secretion of
growth hormone in hyperactive children. J Pediatr 90: 136–139.
19. Bereket A, Turan S, Karaman MG, Haklar G, Ozbay F, et al. (2005) Height,
weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with
attention deficit hyperactivity disorder: effect of methylphenidate treatment.
Horm Res 63: 159–164.
20. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, et al. (1996)
Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle.
J Am Acad Child Adolesc Psychiatry 35: 409–432.
21. Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, et al.
(2003) GH treatment and its effect on bone mineral density, bone maturation
and growth in short children born small for gestational age: 3-year results of a
randomized, controlled GH trial. Clin Endocrinol (Oxf) 59: 779–787.
22. Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, et al. (1999) Growth
hormone treatment in children with short stature born small for gestational age:
5-year results of a randomized, double-blind, dose-response trial. J Clin
Endocrinol Metab 84: 3064–3070.
23. van der Kaay D, Deal C, de Kort S, Willemsen R, Leunissen R, et al. (2009)
Insulin-like growth factor-binding protein-1: serum levels, promoter polymor-
phism, and associations with components of the metabolic syndrome in short
subjects born small for gestational age. J Clin Endocrinol Metab 94: 1386–1392.
24. van Dijk M, Mulder P, Houdijk M, Mulder J, Noordam K, et al. (2006) High
serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I)
during high-dose GH treatment in short children born small for gestational age.
J Clin Endocrinol Metab 91: 1390–1396.
25. Lem AJ, Jobse I, van der Kaay DC, de Ridder MA, Raat H, et al. (2012) Health-
Related Quality of Life in Short Children Born Small for Gestational Age:
Effects of Growth Hormone Treatment and Postponement of Puberty. Horm
Res Paediatr.
26. Usher R, McLean F (1969) Intrauterine growth of live-born Caucasian infants at
sea level: standards obtained from measurements in 7 dimensions of infants born
between 25 and 44 weeks of gestation. J Pediatr 74: 901–910.
27. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, et al.
(2000) Continuing positive secular growth change in The Netherlands 1955–
1997. Pediatr Res 47: 316–323.
28. Tanner JM, Whitehouse RH (1976) Clinical longitudinal standards for height,
weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child
51: 170–179.
29. Hokken-Koelega AC, Hackeng WH, Stijnen T, Wit JM, de Muinck Keizer-
Schrama SM, et al. (1990) Twenty-four-hour plasma growth hormone (GH)
profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II
levels in prepubertal children with chronic renal insufficiency and severe growth
retardation. J Clin Endocrinol Metab 71: 688–695.
30. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, et al. (1998)
Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding
protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res
50: 166–176.
31. van der Reijden-Lakeman IE, de Sonneville LM, Swaab-Barneveld HJ, Slijper
FM, Verhulst FC (1997) Evaluation of attention before and after 2 years of
growth hormone treatment in intrauterine growth retarded children. J Clin Exp
Neuropsychol 19: 101–118.
32. Beck L, Langford WS, Mackay M, Sum G (1975) Childhood chemotherapy and
later drug abuse and growth curve: a follow-up study of 30 adolescents.
Am J Psychiatry 132: 436–438.
33. Hechtman L, Weiss G, Perlman T (1984) Young adult outcome of hyperactive
children who received long-term stimulant treatment. J Am Acad Child
Psychiatry 23: 261–269.
34. Indredavik MS, Vik T, Heyerdahl S, Kulseng S, Brubakk AM (2005) Psychiatric
symptoms in low birth weight adolescents, assessed by screening questionnaires.
Eur Child Adolesc Psychiatry 14: 226–236.
35. Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S (2000) Predictors of
adult height and weight in boys treated with methylphenidate for childhood
behavior problems. J Am Acad Child Adolesc Psychiatry 39: 517–524.
36. Klein RG, Landa B, Mattes JA, Klein DF (1988) Methylphenidate and growth
in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45:
1127–1130.
37. Pliszka SR, Matthews TL, Braslow KJ, Watson MA (2006) Comparative effects
of methylphenidate and mixed salts amphetamine on height and weight in
children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc
Psychiatry 45: 520–526.
38. Safer DJ, Allen RP, Barr E (1975) Growth rebound after termination of
stimulant drugs. J Pediatr 86: 113–116.
39. Sund AM, Zeiner P (2002) Does extended medication with amphetamine or
methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 56:
53–57.
40. Toren P, Silbergeld A, Eldar S, Laor N, Wolmer L, et al. (1997) Lack of effect of
methylphenidate on serum growth hormone (GH), GH-binding protein, and
insulin-like growth factor I. Clin Neuropharmacol 20: 264–269.
MP and the Response to GH in Short SGA Children
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e53164
